Long noncoding RNAs and neuroblastoma

Gaurav Kumar Pandey and Chandrasekhar Kanduri _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:18265-18275. https://doi.org/10.18632/oncotarget.4251

Metrics: PDF 3111 views  |   HTML 3235 views  |   ?  


Gaurav Kumar Pandey1, Chandrasekhar Kanduri1

1Department of Medical Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Correspondence to:

Chandrasekhar Kanduri, e-mail: [email protected]

Keywords: noncoding RNA, neuroblastoma, MYCN, NBAT1, neuronal differentiation

Received: April 09, 2015     Accepted: May 29, 2015     Published: June 10, 2015


Neuroblastoma is a disease that affects infants and despite intense multimodal therapy, high-risk patients have low survival rates (<50%). In recent years long noncoding RNAs (lncRNAs) have become the cutting edge of cancer research with inroads made in understanding their roles in multiple cancer types, including prostate and breast cancers. The roles of lncRNAs in neuroblastoma have just begun to be elucidated. This review summarises where we are with regards to lncRNAs in neuroblastoma. The known mechanistic roles of lncRNAs during neuroblastoma pathogenesis are discussed, as well as the relationship between lncRNA expression and the differentiation capacity of neuroblastoma cells. We speculate about the use of some of these lncRNAs, such as those mapping to the 6p22 hotspot, as biomarkers for neuroblastoma prognosis and treatment. This novel way of thinking about both neuroblastoma and lncRNAs brings a new perspective to the prognosis and treatment of high-risk patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4251